Last reviewed · How we verify
NCT04256343: D2O-MPS
D2O Dosing Strategies to Assess Muscle Protein Synthesis
NA trial testing Deuterium Oxide (D2O) Dose in Hypertrophy. Withdrawn.
31 December 2020
Quick facts
| Lead sponsor | McMaster University |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Start date | 1 May 2020 |
| Primary completion | 31 December 2020 |
| Estimated completion | 1 June 2021 |
Drugs / interventions tested
- Deuterium Oxide (D2O) Dose
Conditions studied
- Hypertrophy — all drugs for Hypertrophy →
Sponsor
McMaster University
Who can join
Adults 18 to 35, any sex, with Hypertrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Skeletal muscle mass is regulated by the balance of muscle protein synthesis (MPS) and muscle protein breakdown (MPB). MPS is sensitive to exogenous stimuli, particularly exercise and protein ingestion. Much of what the investigators currently know about the impact of exercise and protein feeding on MPS has been derived from acute stable isotopic tracers in a controlled laboratory setting. However, recently, the field of skeletal muscle protein metabolism has moved towards the use of deuterium oxide (deuterated water (D2O)) to measure MPS. The ease of administration and the scope to measure turnover in a range of substrates whilst negating the need for strictly controlled laboratory settings makes D2O the ideal candidate to provide a more holistic view of in vivo skeletal muscle metabolism.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04256343
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertrophy
Currently open trials in the same condition.
- NCT06573086 — Resistance Training, Detraining, and Retraining Study 2024 (TraDeRe2024) · NA · recruiting
- NCT05774444 — Investigating the Effects of Krill Oil and Krill Protein on Post-exercise Muscle Protein Metabolism · NA · recruiting
- NCT04514744 — Dynamic Proteomics and Integrated Rates of Muscle Protein Synthesis During an Acute Period of Loading and Unloading · NA · active not recruiting
Other McMaster University trials
Trials by the same sponsor.
- NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
- NCT07213492 — Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder · NA · recruiting
- NCT07486505 — Mindfulness in Fracture Recovery and Reduction of Opioid Reliance: Evaluating the Feasibility of Implementing a Brief, M · NA · not yet recruiting
- NCT07408128 — Partner4Exercise Randomized Controlled Trial · Phase 2, PHASE3 · not yet recruiting
- NCT07459777 — Early arthroscoPic Stabilization veRsus rehabilitatiOn of the Shoulder in Adolescents With a trauMatic First-time Anteri · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04256343 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by McMaster University
- Last refreshed: 15 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04256343.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing